You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR mutant NSCLC

Showing 1 - 25 of 5,196
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Recruiting
  • Non-small Cell Lung Cancer
    • Guanzhou, China
      Sun Yat-sen University Cancer Center
    Aug 11, 2023

    NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +2 more
    • (no location specified)
    Mar 27, 2023

    NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

    Not yet recruiting
    • Non-Small Cell Lung Cancer Metastatic
    • Seoul, Gangnam-gu, Korea, Republic of
      Samsung Medical Center
    Oct 27, 2023

    NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

    Not yet recruiting
    • NSCLC
    • Oral S-1 + Oral Osimertinib
    • Singapore, Singapore
      National Cancer Center Singapore
    Mar 6, 2023

    Non Small Cell Lung Cancer Trial in Seoul (Lazertinib+Pemetrexed+Carboplatin, Lazertinib)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Aug 31, 2023

    EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

    Not yet recruiting
    • EGF-R Positive Non-Small Cell Lung Cancer
    • +4 more
    • Stereotactic Body Radiation Therapy SBRT
    • Bogotá, Colombia
      CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
    Aug 16, 2023

    Non Small Cell Lung Cancer Trial in Italy (Osimertinib)

    Recruiting
    • Non Small Cell Lung Cancer
    • Ancona, Italy
    • +10 more
    Mar 14, 2023

    EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)

    Active, not recruiting
    • EGFR-mutant Non-small Cell Lung Cancer
    • Toronto, Ontario, Canada
    • +10 more
    Dec 5, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

    Not yet recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +2 more
    • Cetuximab
    • +2 more
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Oct 2, 2023

    NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 23, 2023

    NSCLC (NSCLC) Trial in Duarte, Dallas (Osimertinib, SABR)

    Active, not recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • Duarte, California
    • +1 more
    May 13, 2022

    Nsclc Trial in Spain (Repotrectinib, Osimertinib)

    Recruiting
    • Nsclc
    • Málaga, Andalucia, Spain
    • +3 more
    Jun 29, 2022

    NSCLC Trial (PM8002, Placebo, Carboplatin)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Feb 23, 2023

    NSCLC, EGFR Activating Mutation Trial in Guangzhou (Sintilimab, Carboplatin, Nab paclitaxel)

    Recruiting
    • Non-small Cell Lung Cancer
    • EGFR Activating Mutation
    • Sintilimab
    • +2 more
    • Guangzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Aug 8, 2022

    NSCLC Trial (Almonertinib Envafolimab)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Almonertinib Envafolimab
    • (no location specified)
    Sep 10, 2022

    EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

    Recruiting
    • EGFR Exon 20 Mutation
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 12, 2022

    NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation Trial in Nanchang (Almonertinib, Bevacizumab)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Nanchang, Jiangxi, China
      The Second Afiliated Hospital of Nanchang University
    Jun 26, 2021

    Non-Small-Cell Lung Cancer Trial in Shanghai (Furmonertinib (160mg))

    Recruiting
    • Non-Small-Cell Lung Cancer
    • Furmonertinib (160mg)
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Aug 2, 2022

    Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

    Recruiting
    • Lung Neoplasm
    • +26 more
    • Boston, Massachusetts
    • +6 more
    Jun 23, 2022

    EGFR Mutant Advanced NSCLC Trial (JIN-A02)

    Not yet recruiting
    • EGFR Mutant Advanced Non-small Cell Lung Cancer
    • (no location specified)
    Jul 8, 2022

    EGFR, NSCLC, Third-generation TKI Trial (Almonertinib and metronomic oral vinorelbine)

    Not yet recruiting
    • EGFR
    • +2 more
    • Almonertinib and metronomic oral vinorelbine
    • (no location specified)
    Dec 21, 2022

    Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

    Not yet recruiting
    • Lung Cancer Stage IV
    • EGFR T790M
    • Seoul, MA, Korea, Republic of
      Samsung Medical Center
    Jan 26, 2023

    MRD Trial in China (Adjuvant treatment for MRD positivity)

    Recruiting
    • MRD
    • Adjuvant treatment for MRD positivity
    • Beijing, China
    • +15 more
    Sep 12, 2022

    EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
      • Changsha, Hunan, China
        Yongchang Zhang
      Feb 28, 2022

      NSCLC Trial in Chattanooga, Nashville (Aumolertinib, Osimertinib)

      Not yet recruiting
      • NSCLC
      • Chattanooga, Tennessee
      • +1 more
      Aug 16, 2022